Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances (METALIP)

A

Asociacion para el Estudio de las Enfermedades Infecciosas

Status

Completed

Conditions

Lipodystrophy
Metabolic Syndrome

Treatments

Other: Evaluation of changes in fat by DXA while on current therapy
Other: Evaluation of metabolic syndrome

Study type

Observational

Funder types

NETWORK

Identifiers

NCT02614027
460/15
EC 460/15 (Other Identifier)

Details and patient eligibility

About

To evaluate the prevalence of lipodystrophy syndrome in patients receiving currently available antiretroviral drugs, and the prevalence of associated metabolic syndrome in HIV-infected patients with a previous diagnosis of lipodystrophy syndrome, according to the severity of fat accumulation and antiretroviral drug use.

Full description

Cross-sectional evaluation of two groups of patients: patients receiving currently available drugs, in order to determine the changes in fat accumulation by successive dual X-ray absorptiometry (DXA) determinations patients with previous lipodystrophy syndrome, as evaluated by questionnaire (HOPS) and total body dual X-ray absorptiometry (DXA), in order to determine the prevalence of hypertension, low high density lipoprotein (HDL)-cholesterol, glucose disturbance (insulin resistance or diabetes), fat accumulation (waist circumference) and hypertriglyceridemia. The prevalence of Metabolic syndrome will be evaluated according to the different definitions (IDF, NCEP-ATP III, WHO).

Enrollment

276 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV infection
  • Older than 18 years
  • Receiving first or second antiretroviral regimen or
  • Previous evaluation and classification of lipodystrophy syndrome

Exclusion criteria

  • Pregnancy
  • Diagnosis of hypothyroidism, Cushing's syndrome or prolonged intake of corticosteroids or hormones before inclusion
  • Patients who had received antiretroviral drugs known to produce fat disturbances (for lipodystrophy prevalence objective)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems